On April 24, 2020, Akcea Therapeutics, Inc. appointed Robert Dolski as principal financial and accounting officer of the Company. Mr. Dolski has served as Vice President, Finance of the Company since May 2019, and will serve as principal financial and accounting officer on a temporary basis until a replacement principal financial and accounting officer joins the Company. Mr. Dolski joined the Company in May 2019 as Vice President, Finance, responsible for Akcea's accounting operations, securities filings reporting, financial planning and treasury activities.

Prior to joining Akcea, from June 2016 to May 2019, Mr. Dolski was Vice President, Head of Financial Planning and Analysis at Moderna, Inc. and from December 2013 to June 2016, Mr. Dolski was Senior Director, Finance at Forum Pharmaceuticals Inc. In addition, from January 2013 to November 2013, Mr. Dolski was an independent finance consultant to multiple healthcare, start-up companies, and from April 2007 to December 2012, Mr. Dolski was with Human Genome Sciences Inc., serving in various leadership roles, including as Vice President, Finance and Treasury where he helped build the financial planning and analysis function.